Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena submitted a New Drug Application (NDA) for lorcaserin to the FDA in December 2009, and the FDA issued a Complete Response Letter (CRL) in October 2010. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA.

Lorcaserin Phase 3 Clinical Trial Program OverviewThe lorcaserin Phase 3 clinical trial program consists of three double-blind, randomized, placebo-controlled trials – BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) – that together enrolled approximately 7,800 patients. BLOOM and BLOSSOM evaluated lorcaserin versus placebo in obese patients or overweight patients with at least one weight-related co-morbid condition. BLOOM evaluated 3,182 patients over a two-year treatment period, and BLOSSOM evaluated 4,008 patients over a one-year treatment period. BLOOM-DM evaluated 604 obese and overweight patients with type 2 diabetes over a one-year treatment period. The trials included a standardized program of moderate diet and exercise guidance.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major th
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   Cypher ... today announced new data showing that, compared to ... technology provided highly equivalent interpretations of whether ... and did so in a fraction of the ... way for more comprehensive genetic analysis in non-invasive ...
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
(Date:3/27/2015)... 2015 According to a new ... (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab ... VT, WPW) - Global Forecasts to 2019 ", published by ... around ~$4.73 Billion by 2019 with a CAGR of ... Browse   90   ma ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Instrument announced the award of two contracts from the ... Evaluation and Research (CDER).  The first award is a ... Warehouse, and the second award supports the expansion of ... Mortara has a long-standing relationship with ...
... Sept. 30 HHS, Agency for Healthcare Research and ... grants and contracts to support projects that will help ... evidence of effectiveness. The funding announced today covers all ... HHS Secretary by AHRQ.   The projects ...
Cached Medicine Technology:Mortara Instrument Announces ECG Warehouse Contract Awards With US FDA 2HHS Awards $473 Million in Patient-Centered Outcomes Research Funding 2
(Date:3/30/2015)... Daily sun exposure, stressors and environmental ... wrinkles, folds and other giveaways of age. However, advances ... women to hit the pause button, delaying the impact ... tuck or hack to rejuvenate any facial feature. , ... Surgery (AAFPRS) explores the intricacies of The Aging ...
(Date:3/30/2015)... Considered to be the best assessment tool for ... community, this next generation of the IT Audit ... data and frameworks with virtually endless possibilities. These new ... logic features are a technological force to be reckoned ... “The IT Audit Machine is just one of the ...
(Date:3/30/2015)... March 30, 2015 Cutting-edge doctors and ... 2015 Conference because of the opportunities to present and ... conference will highlight parents of recovered children, who will ... Romaniec, will debut her book Victory over Autism: Practical ... Free copies of Victory over Autism will be available ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Developing new ... to the use of cellular models that recapitulate only ... entirety of the disease. , A company that ... cells to precise specifications has created iPSC-derived cardiomyocytes ... environmentally and genetically driven in vitro models of Diabetes ...
(Date:3/29/2015)... At the 2015 International Health Racquet & ... the new Fonda wall mounted heater and a continuing ... and facilities managers with saunas smaller than 425 cubic ... the Fonda heater. With an attractive seamless red ... upgrade for a sauna, especially when mounted in front ...
Breaking Medicine News(10 mins):Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:Helo Commercial Introduces Fonda Sauna Heater and Sauna and Steam Continuing Education Program at IHRSA 2
... Sweden have successfully transferred a uterus into a sheep, and ... They explained that the operation proves that a womb can ... an animal. ,Tests that were conducted on the ... surgery and is continuing to function normally. It was explained ...
... been found to have a role in the treatment of ... // ,The results of the study have been ... Journal of Medicine, which has revealed that this immunosuppressive drug ... as well as the quality of life for people with ...
... forensic medicine lecturer faces disbarment from Medical Council of India (MCI) ... the same time, which is against the rules of the MCI. ... his employment with Sion Hospital. ,If he is debarred, ... has already been debarred till July 31, 2007 for an earlier ...
... to buy Swedish medical company Biacore to complement its ... announced. // ,The Fairfield, Connecticut-based GE will ... for 3.22 billion Swedish kroner ($438 million). ... percent stake in Uppsala, Sweden-based Biacore, supports the bid, ...
... to thee?' - sounds odd?,But it is a dyslexic's mode ... , The learning disability, dyslexia, has a genetic component, ... opens up ways for treatment. , Dyslexia ... Network report that they have located the dyslexia gene, denoted ...
... insisted that hospital consultants who are not referring patients to ... concerns that the NTPF has only seen a fraction of ... ,NTPF chairman Pat O'Byrne commented that there was no ... months for a surgical procedure. ,"There's no doubt ...
Cached Medicine News:Health News:Scientists Claim Human Womb Transplants Possible 2Health News:Cancer Drug to Treat Scleroderma Lung Disease 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: